{"id":"ctace","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hepatotoxicity"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea and vomiting"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This approach allows for high concentrations of chemotherapy to be delivered directly to the tumor site, minimizing systemic side effects. The chemotherapy drugs used in cTACE are typically lipophilic and can be formulated to be released slowly over time, providing a sustained antitumor effect.","oneSentence":"cTACE involves the direct injection of chemotherapy drugs into liver tumors via the hepatic artery.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:11.581Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma"},{"name":"Metastatic liver cancer"}]},"trialDetails":[{"nctId":"NCT07480382","phase":"NA","title":"Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC","status":"NOT_YET_RECRUITING","sponsor":"Hong Wu","startDate":"2026-04-01","conditions":"Initially Unresectable Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT04301778","phase":"PHASE2","title":"Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-08-24","conditions":"Unresectable Intrahepatic Cholangiocarcinoma","enrollment":5},{"nctId":"NCT04777851","phase":"PHASE3","title":"Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7","status":"TERMINATED","sponsor":"Translational Research in Oncology","startDate":"2023-10-11","conditions":"Carcinoma, Hepatocellular","enrollment":45},{"nctId":"NCT05016245","phase":"PHASE3","title":"MANDARIN (S6371)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2021-09-13","conditions":"Inoperable Hepatocellular Carcinoma","enrollment":92},{"nctId":"NCT07334483","phase":"PHASE2","title":"A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC","status":"RECRUITING","sponsor":"GrandPharma (China) Co., Ltd.","startDate":"2025-08-22","conditions":"HCC","enrollment":120},{"nctId":"NCT07322848","phase":"PHASE3","title":"DEB-TACE vs cTACE in HCC After TIPS","status":"RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2025-12-01","conditions":"Hepatocellular Carcinoma (HCC), TACE, TIPS","enrollment":206},{"nctId":"NCT05171166","phase":"PHASE2, PHASE3","title":"Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.","status":"TERMINATED","sponsor":"Peking University","startDate":"2021-12-24","conditions":"Hepatocellular Carcinoma","enrollment":18},{"nctId":"NCT07131501","phase":"PHASE2","title":"A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-08-11","conditions":"Hepatocellular Carcinoma, Immunotherapy, Preoperative","enrollment":48},{"nctId":"NCT07128251","phase":"PHASE2","title":"A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2025-08-20","conditions":"Hepatocellular Carcinoma (HCC), Immunotherapy, PD-1","enrollment":47},{"nctId":"NCT04996914","phase":"NA","title":"Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"RWTH Aachen University","startDate":"2025-09-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":30},{"nctId":"NCT06900543","phase":"PHASE3","title":"Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere","status":"RECRUITING","sponsor":"Chengdu New Radiomedicine Technology Co. LTD.","startDate":"2025-04-15","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":108},{"nctId":"NCT04472767","phase":"PHASE2","title":"Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2020-08-07","conditions":"Hepatocellular Carcinoma, HCC","enrollment":35},{"nctId":"NCT06909708","phase":"NA","title":"SIRT Versus cTACE for Unresectable HCC (CHANCE2506)","status":"RECRUITING","sponsor":"Zhongda Hospital","startDate":"2025-04-03","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":108},{"nctId":"NCT06844357","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.","status":"RECRUITING","sponsor":"Zhejiang Raygene Pharmaceuticals Co., Ltd","startDate":"2025-03-27","conditions":"HCC","enrollment":300},{"nctId":"NCT05984511","phase":"NA","title":"TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2023-08-30","conditions":"Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus","enrollment":234},{"nctId":"NCT06788353","phase":"","title":"Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-03-01","conditions":"Transarterial Chemoembolization, Systemic Therapy, Unresectable Hepatocellular Carcinoma","enrollment":500},{"nctId":"NCT06779461","phase":"PHASE3","title":"A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"InnoBM Pharmaceuticals Co., Ltd.","startDate":"2025-01","conditions":"Hepatocellular Carcinoma Non-Resectable","enrollment":228},{"nctId":"NCT05301842","phase":"PHASE3","title":"Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-03-28","conditions":"Hepatocellular Carcinoma","enrollment":760},{"nctId":"NCT04803994","phase":"PHASE3","title":"The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2021-07-06","conditions":"Hepatocellular Carcinoma","enrollment":434},{"nctId":"NCT04523350","phase":"NA","title":"Instylla HES Hypervascular Tumor Pivotal Study","status":"COMPLETED","sponsor":"Instylla, Inc.","startDate":"2021-01-04","conditions":"Hypervascular Tumors","enrollment":150},{"nctId":"NCT03268499","phase":"NA","title":"Emulsion Versus Suspension in Chemoembolization for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2016-09-09","conditions":"Hepatocellular Carcinoma","enrollment":80},{"nctId":"NCT06090656","phase":"PHASE2","title":"Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-03-02","conditions":"Hepatocellular Carcinoma","enrollment":88},{"nctId":"NCT04842565","phase":"PHASE2","title":"cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria","status":"COMPLETED","sponsor":"Fudan University","startDate":"2021-05-01","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT04103398","phase":"PHASE3","title":"TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2019-10-02","conditions":"Hepatocellular Carcinoma, Sorafenib, Transarterial Chemoembolization","enrollment":162},{"nctId":"NCT06261138","phase":"","title":"Survival Analysis: TACE vs. Combination Therapy in HCC","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-02-01","conditions":"Hepatocellular Carcinoma","enrollment":279},{"nctId":"NCT05103007","phase":"NA","title":"PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2021-12-01","conditions":"Hepatocellular Carcinoma","enrollment":200},{"nctId":"NCT04975932","phase":"","title":"Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study","status":"COMPLETED","sponsor":"Zhongda Hospital","startDate":"2021-07-01","conditions":"Hepatocellular Carcinoma","enrollment":826},{"nctId":"NCT05925413","phase":"PHASE2","title":"Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2023-04-24","conditions":"Hepatocellular Carcinoma","enrollment":41},{"nctId":"NCT05704192","phase":"","title":"CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2023-05-04","conditions":"Hepatocellular Carcinoma, Portal Hypertension","enrollment":373},{"nctId":"NCT05703750","phase":"","title":"Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301)","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2023-05-04","conditions":"Hepatocellular Carcinoma, Portal Hypertension","enrollment":228},{"nctId":"NCT04635527","phase":"PHASE1","title":"A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2020-12-24","conditions":"Hepatocellular Carcinoma","enrollment":10},{"nctId":"NCT05760430","phase":"PHASE2","title":"The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-12-14","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT05592197","phase":"NA","title":"Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT","status":"WITHDRAWN","sponsor":"Sun Yat-sen University","startDate":"2018-10-01","conditions":"Advanced Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT05718232","phase":"PHASE3","title":"SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-03","conditions":"Advanced Hepatocellular Carcinoma","enrollment":136},{"nctId":"NCT05332496","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":220},{"nctId":"NCT05631613","phase":"","title":"Lipiodol-TACE With Idarubicin Based On a Specific Emulsion Ratio for Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT05332821","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":474},{"nctId":"NCT05316077","phase":"","title":"Safety and Performance of Vectorio® in Conventional Trans-Arterial Chemo-Embolization (cTACE): A Post-Market Clinical Follow-up","status":"UNKNOWN","sponsor":"Guerbet","startDate":"2022-08-30","conditions":"Oncology","enrollment":50},{"nctId":"NCT04967482","phase":"NA","title":"DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2021-07-09","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":216},{"nctId":"NCT05472896","phase":"PHASE3","title":"TACE With Dicycloplatin(TP21) in Unresectable HCC","status":"UNKNOWN","sponsor":"Gao-jun Teng","startDate":"2022-06-09","conditions":"Hepatocellular Carcinoma","enrollment":332},{"nctId":"NCT05233358","phase":"NA","title":"HAIC Combined With Second-line \"Target Immunity\" for HCC With TACE Standard Treatment Low Response or Failure","status":"UNKNOWN","sponsor":"The Central Hospital of Lishui City","startDate":"2022-02-01","conditions":"Hepatocellular Carcinoma","enrollment":176},{"nctId":"NCT05025592","phase":"","title":"cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-09-10","conditions":"HCC, Transarterial Chemoembolization, Hepatic Arterial Infusion Chemotherapy","enrollment":60},{"nctId":"NCT04127396","phase":"PHASE4","title":"Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2019-09-01","conditions":"Carcinoma, Hepatocellular, Portal Vein Tumor Thrombus","enrollment":72},{"nctId":"NCT04517227","phase":"NA","title":"The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-07","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT04738188","phase":"NA","title":"Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;","status":"UNKNOWN","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2020-03-18","conditions":"Hepatocellular Carcinoma","enrollment":226},{"nctId":"NCT04721470","phase":"NA","title":"Combined Therapy for Hepatocellular Carcinoma >3-<5 cm","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2017-01-01","conditions":"Hepatocellular Carcinoma","enrollment":278},{"nctId":"NCT04479527","phase":"PHASE2","title":"Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-04","conditions":"Hepatocellular Carcinoma","enrollment":34},{"nctId":"NCT04652492","phase":"PHASE2","title":"Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2020-10-27","conditions":"Hepatocellular Carcinoma","enrollment":72},{"nctId":"NCT04597970","phase":"PHASE2","title":"TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2020-10-20","conditions":"Transarterial Chemoembolization, Hepatocellular Carcinoma","enrollment":66},{"nctId":"NCT03007225","phase":"PHASE4","title":"Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2015-07","conditions":"HepatoCellular Carcinoma","enrollment":50},{"nctId":"NCT02753881","phase":"PHASE1","title":"Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2015-11","conditions":"Liver Cancer","enrollment":30},{"nctId":"NCT04143191","phase":"PHASE3","title":"Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-09-15","conditions":"Hepatocellular Carcinoma","enrollment":158},{"nctId":"NCT03969576","phase":"NA","title":"Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2020-09-15","conditions":"Hepatocellular Carcinoma","enrollment":344},{"nctId":"NCT02994251","phase":"PHASE2","title":"A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma","status":"TERMINATED","sponsor":"Yale University","startDate":"2017-06-21","conditions":"Unresectable Intrahepatic Cholangiocarcinoma","enrollment":1},{"nctId":"NCT03905967","phase":"PHASE3","title":"TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-06-16","conditions":"Advanced Hepatocellular Carcinoma","enrollment":336},{"nctId":"NCT02173119","phase":"","title":"Can Quantitative MRI After cTACE Help Predict Survival ?","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2014-08","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":23},{"nctId":"NCT01829035","phase":"PHASE3","title":"A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2013-02-21","conditions":"Advanced Adult Hepatocellular Carcinoma","enrollment":339},{"nctId":"NCT02908165","phase":"PHASE2","title":"Randomized Phase II Trial of Chemoembolization and Sorafenib","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2016-06","conditions":"Hepatocellular Carcinoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":380,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["transarterial chemoembolization"],"phase":"phase_3","status":"active","brandName":"cTACE","genericName":"cTACE","companyName":"Chengdu New Radiomedicine Technology Co. LTD.","companyId":"chengdu-new-radiomedicine-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"cTACE involves the direct injection of chemotherapy drugs into liver tumors via the hepatic artery. Used for Hepatocellular carcinoma, Metastatic liver cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}